Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ATOS
- CUSIP: N/A
- Web: www.atossagenetics.com
Capitalization:- Market Cap: $3.32 million
- Outstanding Shares: 7,412,000
Average Prices:- 50 Day Moving Avg: $0.48
- 200 Day Moving Avg: $0.92
- 52 Week Range: $0.34 - $4.35
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.18
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.40 per share
- Price / Book: 0.95
Profitability:- EBIDTA: ($6,370,000.00)
- Return on Equity: -161.74%
- Return on Assets: -125.73%
Debt:- Current Ratio: 1.96%
- Quick Ratio: 1.96%
Misc:- Average Volume: 295,527 shs.
- Beta: 1.48
- Short Ratio: 1.83
Frequently Asked Questions for Atossa Genetics (NASDAQ:ATOS)
What is Atossa Genetics' stock symbol?
Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."
How were Atossa Genetics' earnings last quarter?
Atossa Genetics Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.02. View Atossa Genetics' Earnings History.
When will Atossa Genetics make its next earnings announcement?
Who are some of Atossa Genetics' key competitors?
Some companies that are related to Atossa Genetics include PhotoMedex (PHMD), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI), Hansen Medical (HNSN), Lifeline Scientific (LSIC), Mindray Medical International Ltd (MR), Nanosphere (NSPH), Sirona Dental Systems (SIRO), Synergetics USA (SURG), Thoratec (THOR), Volcano Corp (VOLC) and Zeltiq Aesthetics (ZLTQ).
Who are Atossa Genetics' key executives?
Atossa Genetics' management team includes the folowing people:
- Steven C. Quay M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
- Kyle Guse Esq., CPA, Chief Financial Officer, General Counsel, Secretary
- Cindy Atha, Vice President of Sales and Marketing
- Janet Rose Rea MSPH, Vice President - Regulatory Affairs and Quality
- Shu-Chih Chen Ph.D., Director
- Stephen J. Galli M.D., Independent Director
- H. Lawrence Remmel Esq., Independent Director
- Richard I. Steinhart CPA, Independent Director
- Gregory L. Weaver, Independent Director
How do I buy Atossa Genetics stock?
Shares of Atossa Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atossa Genetics' stock price today?
One share of Atossa Genetics stock can currently be purchased for approximately $0.38.
MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Atossa Genetics (NASDAQ:ATOS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Atossa Genetics (NASDAQ:ATOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Atossa Genetics (NASDAQ:ATOS)Earnings History by Quarter for Atossa Genetics (NASDAQ ATOS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/10/2017 | | | | | | | N/A |  |
| 11/14/2016 | Q316 | ($1.28) | $0.07 | | | View | N/A | |
| 8/12/2016 | Q2 | ($0.07) | ($0.05) | | | View | N/A | |
| 5/5/2016 | Q116 | | ($0.07) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.11) | ($0.15) | $2.80 million | $0.77 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.12) | ($0.11) | $2.05 million | $2.69 million | View | N/A | |
| 5/13/2015 | Q1 | ($0.11) | ($0.13) | $1.00 million | $1.87 million | View | Listen | |
| 3/30/2015 | Q4 2014 | ($0.11) | ($0.24) | $0.10 million | $0.49 million | View | N/A | |
| 11/12/2014 | Q314 | | ($0.13) | $76.60 million | $3.40 million | View | N/A | |
| 8/12/2014 | Q214 | | ($0.23) | | $0.01 million | View | N/A | |
| 5/14/2014 | Q114 | ($0.11) | ($0.10) | $1.93 million | $0.02 million | View | N/A | |
| 3/27/2014 | Q4 2013 | ($0.20) | ($0.15) | $0.02 million | $0.05 million | View | N/A | |
| 11/12/2013 | | ($0.15) | ($0.22) | | | View | N/A | |
| 8/14/2013 | Q213 | | ($0.17) | $0.28 million | $0.33 million | View | N/A | |
| 5/15/2013 | Q113 | ($0.11) | ($0.14) | $0.52 million | $0.18 million | View | N/A | |
| 12/20/2012 | Q312 | | ($0.10) | $0.10 million | $0.11 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Atossa Genetics (NASDAQ:ATOS)Current Year EPS Consensus Estimate: $-1.94 EPS
Next Year EPS Consensus Estimate: $-2.09 EPS
Dividend History for Atossa Genetics (NASDAQ:ATOS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Atossa Genetics (NASDAQ:ATOS)Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 4.69%
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/17/2017 | H. Lawrence Remmel | Director | Buy | 2,500 | $0.63 | $1,575.00 | |
| 4/1/2016 | H. Lawrence Remmel | Director | Buy | 1,500 | $0.33 | $495.00 | |
| 3/9/2016 | Steven C Quay | CEO | Buy | 15,000 | $0.37 | $5,550.00 | |
| 2/16/2016 | Shu-Chih Chen | Director | Buy | 15,000 | $0.53 | $7,950.00 | |
| 1/19/2016 | Steven C Quay | CEO | Buy | 50,000 | $0.20 | $10,000.00 | |
| 6/12/2015 | H. Lawrence Remmel | Director | Buy | 5,400 | $1.30 | $7,020.00 | |
| 11/21/2013 | Gregory L Weaver | Director | Buy | 10,000 | $2.58 | $25,800.00 | |
| 10/1/2013 | Steven C Quay | CEO | Sell | 7,265 | $5.66 | $41,119.90 | |
| 1/8/2013 | H. Lawrence Remmel | Director | Buy | 4,000 | $4.12 | $16,480.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Atossa Genetics (NASDAQ:ATOS)
Latest Headlines for Atossa Genetics (NASDAQ:ATOS)
| Source: |
|
| Date | Headline |
|---|
 | Atossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study
finance.yahoo.com - July 25 at 4:02 PM |
| Atossa Genetics Announces Warrant Exercises
finance.yahoo.com - June 30 at 4:15 PM |
| Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
finance.yahoo.com - June 26 at 4:15 PM |
| ATOS: Balance Sheet Boosted by Recent Financing
finance.yahoo.com - June 6 at 3:49 PM |
| Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017
finance.yahoo.com - June 1 at 3:58 PM |
| Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
finance.yahoo.com - May 19 at 9:22 AM |
 | BRIEF-Atossa Genetics qtrly loss per share $0.45
www.reuters.com - May 11 at 9:08 PM |
 | Atossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
www.streetinsider.com - May 11 at 1:53 AM |
| Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
finance.yahoo.com - May 10 at 9:04 AM |
| BRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study
www.reuters.com - May 9 at 8:44 PM |
| Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
finance.yahoo.com - May 9 at 9:06 AM |
 | Atossa Genetics (ATOS) Receives Daily Media Impact Rating of 0.44
www.americanbankingnews.com - April 29 at 9:58 AM |
| Atossa Genetics Inc (ATOS) Short Interest Down 57.8% in April
www.americanbankingnews.com - April 29 at 7:21 AM |
| BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study
www.reuters.com - April 21 at 8:47 PM |
| Atossa Genetics (ATOS) Receives News Sentiment Rating of 0.29
www.americanbankingnews.com - April 21 at 10:49 AM |
| Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
finance.yahoo.com - April 20 at 3:45 PM |
| Atossa Genetics (ATOS) Getting Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 12:16 PM |
| Atossa Genetics (ATOS) Given Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - April 14 at 5:21 PM |
| Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
finance.yahoo.com - April 7 at 8:13 AM |
| Atossa Genetics Closes Public Offering
finance.yahoo.com - April 4 at 4:26 AM |
 | Atossa Genetics, Inc. Prices $4,000,000 Public Offering
us.rd.yahoo.com - March 29 at 3:54 PM |
| 3:48 am Atossa Genetics prices $4 mln public offering consisting of units, common stock and warrants
us.rd.yahoo.com - March 29 at 3:54 PM |
 | Seattle breast cancer company stock plummets as it seeks funding to continue operations
www.bizjournals.com - March 29 at 3:54 PM |
| Atossa Genetics (ATOS) Confirms Pricing of $4M Public Offering
www.streetinsider.com - March 29 at 12:53 PM |
| BRIEF-Atossa Genetics prices $4 mln public offering
www.reuters.com - March 29 at 12:53 PM |
| BRIEF-Atossa Genetics files for public offering of up to 4 mln units
www.reuters.com - March 23 at 4:08 PM |
| Atossa Genetics Opens Enrollment in Study of Endoxifen
finance.yahoo.com - March 23 at 4:08 PM |
| ATOSSA GENETICS INC Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 21 at 12:32 PM |
| ATOSSA GENETICS INC Files SEC form 10-Q/A, Quarterly Report
biz.yahoo.com - March 21 at 12:32 PM |
| ATOS: Pure Player in the Breast Care Space
finance.yahoo.com - March 17 at 4:21 PM |
| ATOSSA GENETICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:11 PM |
| IPOs & Transactions Week in Review: Feb 13 - 17 / plus "Billion Dollar Questions" M&A whitepaper
www.bizjournals.com - February 20 at 3:37 PM |
| Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
finance.yahoo.com - January 9 at 4:49 PM |
| 8:21 am Atossa Genetics transfers the site of its Phase 2 study of fulvestrant in order to facilitate faster enrollment, which co now anticipates completing by August 2017
finance.yahoo.com - January 9 at 4:49 PM |
| Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017
finance.yahoo.com - January 5 at 9:02 PM |
| Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016
finance.yahoo.com - December 1 at 3:45 PM |
| ATOSSA GENETICS INC Financials
finance.yahoo.com - November 22 at 1:44 PM |
| ATOSSA GENETICS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 18 at 1:05 PM |
| ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
biz.yahoo.com - November 18 at 1:05 PM |
| ATOS: Update on Third Quarter Financials
finance.yahoo.com - November 17 at 1:59 PM |
 | Atossa Genetics' (ATOS) CEO Steven Quay on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 3:46 PM |
| Q3 2016 Atossa Genetics Inc Earnings Release - After Market Close
biz.yahoo.com - November 14 at 9:52 AM |
 | ATOSSA GENETICS INC
www.finanznachrichten.de - November 11 at 8:22 PM |
| SeeThruEquity Issues Update on Atossa Genetics, Inc.
finance.yahoo.com - October 3 at 3:33 PM |
| ATOSSA GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement
biz.yahoo.com - September 3 at 9:12 AM |
| BRIEF-Atossa prices underwritten public offering of 1,150,000 common shares
www.reuters.com - September 1 at 12:04 PM |
| Atossa Genetics (ATOS) Prices 1.15M Share Common Stock Offering for Proceeds of ~$2.88M
www.streetinsider.com - September 1 at 12:04 PM |
Atossa Genetics (ATOS) Chart for Wednesday, July, 26, 2017
